Research Indications: Analgesic Research, Addiction Research, Anxiolytic Research, Sleep Research,
11 Item Items
Warning: Last items in stock!
SOMA-OX Stephania Optimized Modulation Agent Optimized Xtract Formulation
SOMA-OX is a proprietary herbal extract derived from Stephania genus optimized to foster modulation of pathways that promote analgesic-sparing, tolerance sparing, and adverse effects sparing outcomes within pain management protocols.
SOMA-OX imparts notable muscle relaxant and sedative oriented effects that are dose dependent. It as well imparts a notable facilitation of superior opioidergic signalling and tolerance reduction.
SOMA-OX administered on a per oral twice daily basis in rat and murine models demonstrates strong potentials for high efficacy within multiple addiction cessation paradigms.
SOMA-OX, in early and limited animal research trials, has demonstrated indications of significant anxiolytic, sedative, and relaxant efficacy with concurrent next day antidepressant efficacy when administered to animals as a single dose given p.o. two to four hours prior to sleep cycle in low dose ranges.
Future Human Clinical Testing Protocols Extrapolated from Animal Data:
Analgesia/Anxiolysis: Dose arms of 12.5mg, 25mg, 50mg, and 100mg are anticipated for use within efficacy trials. Expectations predict rapid onset effects of enhancing parameters of benefit as relates to mu-opioid and non-opioid analgesia.
Antidepressant: In a murine animal model for assessment of antidepressant efficacy SOMA-OX demonstrated considerable efficacy at dose equivalent (HED) to 2.5mg, 5mg, and 10mg as to be thought best to be administered once daily 1-4 hours prior to bedtime.
Sedative Capacity: Dose dependent with significance demonstrated at all dosages that would correlate to human equivalent dosages of 25mg and above. Higher end dosages are seen to be intended for use within conditions that have no concern for potential sedative effects. Said higher-end dose range may in particular demonstrate significant evening relaxation and sleep facilitation, critical for chronic pain states and addiction cessartion protocols.
Potentials for trials within multiple addiction cessation paradigms are indicated.
Duration of activity: As qualified per in vivo animal studies deomonstrate a dose dependent efficacy lasting 6-18 hours. Dosing b.i.d. would be indicated for relatively steady state levels of primary actives and consistent maintenance of effect.
Solubility: Freely soluble in alcohol, methanol; insoluble in water (alkaline).
Concurrent administration in mice models in vivo with Alseventin-OA, ENKI-OX, PRAD-OX and ORPA-OX were seen to enhance the rapid-onset degree of efficacy with no increase in sedation.
USAGE: For Research Use Only! Not For Use in Humans!